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E-transporter (4E-T) is one of several proteins that
bind the mRNA 5
 
 
 
cap-binding protein, eukaryotic
initiation factor 4E (eIF4E), through a conserved
binding motif. We previously showed that 4E-T is a nucleo-
cytoplasmic shuttling protein, which mediates the import
of eIF4E into the nucleus. At steady state, 4E-T is predom-
inantly cytoplasmic and is concentrated in bodies that
conspicuously resemble the recently described processing
bodies (P-bodies), which are believed to be sites of
mRNA decay. In this paper, we demonstrate that 4E-T
4
 
colocalizes with mRNA decapping factors in bona ﬁde
P-bodies. Moreover, 4E-T controls mRNA half-life, because
its depletion from cells using short interfering RNA in-
creases mRNA stability. The 4E-T binding partner, eIF4E,
also is localized in P-bodies. 4E-T interaction with eIF4E
represses translation, which is believed to be a prerequi-
site for targeting of mRNAs to P-bodies. Collectively,
these data suggest that 4E-T interaction with eIF4E is a
priming event in inducing messenger ribonucleoprotein
rearrangement and transition from translation to decay.
 
Introduction
 
The regulation of mRNA biogenesis and decay plays an im-
portant role in the control of gene expression. mRNA decay
regulates protein levels, eliminates aberrant mRNAs, and is an
essential host defense mechanism during viral infection (Coller
and Parker, 2004). There are three major mRNA decay pathways
(Coller and Parker, 2004; Parker and Song, 2004). The general
pathway involves deadenylation followed by decapping of the
mRNA. In yeast, transcripts are primarily degraded in a 5
 
 
 
 to
3
 
 
 
 direction by the Xrn1 exonuclease (Muhlrad et al., 1995;
Schwartz and Parker, 1999; Coller and Parker, 2004; Parker and
Song, 2004), whereas in higher eukaryotes, mRNAs mostly are
eliminated in a 3
 
 
 
 to 5
 
 
 
 fashion by the exosome after deadenyla-
tion (Chen et al., 2001; Hilleren et al., 2001; Wang and Kiledjian,
2001; Wilusz et al., 2001; Mukherjee et al., 2002; Tourriere et al.,
2002). mRNA degradation also can occur through a second
pathway that involves endonucleolytic cleavage of mRNAs
(Schoenberg and Chernokalskaya, 1997), and in addition, through
specialized mechanisms, including nonsense-mediated decay and
nonstop decay (for reviews see Wilusz et al., 2001; Tourriere et
al., 2002; Coller and Parker, 2004; Parker and Song, 2004).
mRNA decapping is a crucial step in general and special-
ized mRNA decay (Parker and Song, 2004). Decapping is me-
diated by a heterodimeric complex composed of Dcp1 and
Dcp2 (Beelman et al., 1996; Dunckley and Parker, 1999;
Lykke-Andersen, 2002; van Dijk et al., 2002; Wang et al.,
2002). Numerous factors that regulate decapping activity have
been identified in yeast and mammals. The Lsm 1–7 complex,
Pat1p, Dhh1p, Edc1p, Edc2, and Edc3 are positive regulators
of decapping, characterized in yeast (Coller and Parker, 2004;
Parker and Song, 2004).
Most mammalian mRNAs studied are the target of degra-
dation by the 3
 
 
 
-5
 
 
 
exosome (Chen et al., 2001; Mukherjee et
al., 2002; Wang and Kiledjian, 2001). Nonetheless, decapping
activity similar in function to the yeast Dcp1p has been detected
in HeLa cells (Gao et al., 2001); mammalian homologues of
Dcp1/2 (Lykke-Andersen, 2002; Wang et al., 2002), the Lsm
proteins (Achsel et al., 1999), and Dhh1p (Smillie and Som-
merville, 2002) also exist. Furthermore, Xrn1 homologues
have been identified in mammals (Bashkirov et al., 1997; In-
gelfinger et al., 2002). However, it has not been demonstrated
unequivocally whether deadenylated-decapped mRNAs are
subject to 5
 
 
 
 or 3
 
 
 
 exonucleolytic decay in mammalian cells in
vivo (discussed in Wang and Kiledjian, 2001; Mukherjee et al.,
2002; Wilusz and Wilusz, 2004).
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The mRNA 5
 
 
 
 cap structure and the 3
 
 
 
 polyA tail play
important roles in the decapping process (Wilusz et al., 2001;
Coller and Parker, 2004). The polyA inhibits decapping, likely
through the polyA binding protein (PABP) interaction with
eIF4G, a component of the eIF4F cap-binding complex (Coller
and Parker, 2004). eIF4F also contains the cap binding protein,
eukaryotic initiation factor 4E (eIF4E), and the RNA helicase,
eIF4A (Gingras et al., 1999). The interaction of PABP with
eIF4G enhances the binding of eIF4F to the mRNA (Kahvejian
et al., 2005), and thus, hinders the access of the decapping
complex to the cap. Consequently, translation and decapping
are antagonistic. Consistent with this idea, mutations in eIF4E
and eIF4G can lead to an increase in decapping in yeast
(Schwartz and Parker, 1999). Importantly, decapping requires
the removal of eIF4F from the 5
 
 
 
 cap structure, which, in turn,
necessitates a transition from a translationally active messenger
RNP (mRNP) to one destined for decay. This transition entails
the replacement of initiation factors on the mRNA with decap-
ping factors (Tharun and Parker, 2001; Coller and Parker,
2004; Parker and Song, 2004; Teixeira et al., 2005). The switch
from translation to decay occurs concomitantly with aggrega-
tion of mRNPs into distinct cytoplasmic foci, termed process-
ing bodies (P-bodies), in yeast (Sheth and Parker, 2003), or
GW bodies (Eystathioy et al., 2003) or Dcp1a bodies in mam-
mals (Cougot et al., 2004); these are referred to as P-bodies
throughout this article. The decapping enzyme, Dcp1/2, and
decapping associated factors, Lsm1-7, Dhh1p/p54, and Xrn1,
are concentrated in these foci (Ingelfinger et al., 2002; van Dijk
et al., 2002; Sheth and Parker, 2003; Cougot et al., 2004; Liu et
al., 2004). However, little is known about the recruitment
mechanism of mRNAs to P-bodies, or how initiation factors
are exchanged with decapping enzymes.
We reported earlier the cloning of 4E-transporter (4E-T),
which interacts with eIF4E through a conserved eIF4E recogni-
tion motif (YXXXXL
 
 
 
, where 
 
 
 
 is a hydrophobic amino acid)
that is also found in eIF4G and 4E-BP. 4E-T is a nucleocyto-
plasmic shuttling protein that mediates the nuclear import of
eIF4E through the importin 
 
 
 
/
 
 
 
 pathway. At steady state, 4E-T
is predominantly cytoplasmic and is concentrated in bodies
that conspicuously resemble the recently described P-bodies
(Dostie et al., 2000a; Sheth and Parker, 2003). Here, we report
that 4E-T colocalizes with eIF4E and decapping factors in bona
fide  P-bodies and controls mRNA turnover. Significantly,
depletion of 4E-T from cells enhances mRNA stability.
 
Results
 
4E-T colocalizes with decapping factors
 
To determine whether 4E-T associates with P-bodies, the lo-
calization of 4E-T and P-body components was analyzed by
immunofluorescence in HeLa cells. Cells transfected with
HA–4E-T were analyzed by double-label immunofluorescence
microscopy using anti-HA antibody and an affinity-purified
anti-Dcp1a antibody that recognizes the endogenous protein
(see Materials and methods). Transfected HA–4E-T and en-
dogenous Dcp1a colocalized in the cytoplasm in discrete foci
that strongly resemble P-bodies (Fig. 1 A). Similar results were
obtained with a GFP-tagged 4E-T (Fig. 1 B). To show that en-
dogenous 4E-T also localizes to P-bodies, its colocalization
with Me31B was studied (Me31B is the 
 
Drosophila
 
 homo-
logue of the human decapping factor Dhh1p/p54, and similar to
Dcp1a, is an established marker of P-bodies [Sheth and Parker,
2003; Tseng-Rogenski et al., 2003]; Me31B shares 71% iden-
tity with Dhh1p/p54 and was shown to form cytoplasmic gran-
ules in germline cells [Nakamura et al., 2001]). HeLa cells
transfected with myc-EYFP-Me31B were stained with an af-
finity-purified anti–4E-T antibody, and analyzed by micros-
copy. Endogenous 4E-T colocalizes with myc-EYFP-Me31B
in discrete cytoplasmic foci (Fig. 1 C). Thus, endogenous and
transfected 4E-T colocalize with bona fide decapping factors in
cytoplasmic foci, which fulfill the criteria of P-bodies.
 
4E-T down-regulates
cap-dependent translation
 
In the yeast 
 
Saccharomyces cerevisiae
 
, targeting of mRNAs to
P-bodies is believed to occur as a consequence of cessation of
translation (Schwartz and Parker, 1999; Tharun and Parker,
2001; Teixeira et al., 2005). Thus, it is conceivable that changes
in mRNP composition that lead to translational arrest result in
targeting the mRNA to P-bodies in mammals. 4E-T interacts
with eIF4E through a conserved binding site, which also is
found in eIF4G (Mader et al., 1995), and thus, might promote
targeting of mRNAs to P-bodies by inhibiting translation initia-
Figure 1. 4E-T colocalizes with decapping factors in P-bodies. (A and B)
Transfected 4E-T colocalizes with endogenous Dcp1a. HeLa cells trans-
fected with HA–4E-T (A) or GFP–4E-T (B) were stained with anti-Dcp1a to vi-
sualize endogenous Dcp1a. The localization of HA–4E-T was determined
by indirect immunofluorescence with anti-HA (Covance) and Alexa Fluor
594 anti–mouse IgG. Dcp1a was revealed with anti-Dcp1a and either
Alexa Fluor 488 anti–rabbit IgG (A) or Alexa Fluor 594 anti–mouse IgG (B).
The colocalization of HA–4E-T or GFP–4E-T with Dcp1a appears yellow
(right). (C) Endogenous 4E-T colocalizes with transfected myc-EYFP-Me31B.
HeLa cells were transfected with myc-EYFP-Me31B and colocalization with
endogenous 4E-T was performed with anti–4E-T and Texas Red–conjugated
anti–rabbit IgG. Colocalization appears yellow (right). 
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tion. To address this possibility, the inhibitory effect of 4E-T on
translation was examined in vivo. HeLa cells infected with re-
combinant vaccinia virus vTF7-3 (to synthesize the T7 RNA
polymerase in the cytoplasm) were cotransfected transiently
with plasmid DNA containing a 4E-T cDNA and a bicistronic
reporter construct expressed from a T7 promoter. The bicistronic
reporter construct consists of the luciferase (LUC) and chloram-
phenicol acetyl transferase (CAT) cistrons, separated by the po-
liovirus internal ribosome entry site (IRES; Pause et al., 1994)
(Fig. 2 A). Translation of the LUC cistron proceeds in a cap-
dependent manner, whereas translation of the CAT cistron is
cap-independent and serves as a surrogate control for mRNA
levels. (Note that quantification of the RNA by Northern
blotting could not be performed because the vaccinia virus
T7 system produces heterogenous RNA transcripts, generating
smeared bands [Fuerst and Moss, 1989]. This is attributed to the
lack of an authentic T7 RNA polymerase termination sequence.
However, this has no deleterious effect on mRNA turnover or
translation [Fuerst and Moss, 1989].) Only a fraction (5–10%) of
T7-transcribed RNAs are capped by the vaccinia-capping en-
zyme (Fuerst and Moss, 1989). However, uncapped RNA is
translated inefficiently in vivo and in vitro (Both et al., 1975;
Shatkin, 1976; Sonenberg et al., 1980; Fuerst and Moss, 1989;
Peng and Schoenberg, 2005; and unpublished data). Thus, even
if only a small fraction of the T7-transcribed RNAs is capped in
the T7 vaccinia virus system, the uncapped products largely are
untranslated (
 
 
 
0.4–1% of uncapped compared with capped
RNA; unpublished data). All constructs were expressed to simi-
lar levels (Fig. 2 B, bottom panel, compare lanes 2–4). The bind-
ing of 4E-T to eIF4E was demonstrated by Far Western blotting
with [
 
32
 
P]HMK-eIF4E (Fig. 2 B, lane 2, top panel). The 4E-T
mutant, Y30A, which is mutated in the YXXXXL
 
 
 
 motif, did
not bind to eIF4E, as expected (Fig. 2 B, lane 3, top panel). LUC
expression was decreased significantly by overexpression of
wild-type 4E-T (Fig. 2 C, left, top panel), whereas CAT activity
remained relatively unchanged (Fig. 2 C, left, bottom panel). In
contrast, the Y30A mutant of 4E-T did not affect LUC or CAT
expression. Therefore, overexpression of wild-type 4E-T, but
not the mutant Y30A, strongly inhibited (88%) translation (Fig.
2 C). In conclusion, overexpression of 4E-T in HeLa cells results
in the repression of translation only when bound to eIF4E.
 
eIF4E localizes to P-bodies
 
Because 4E-T localizes to P-bodies, and because it interacts
with eIF4E, it was pertinent to ask whether eIF4E also localizes
to P-bodies, and whether this localization requires 4E-T. To
this end, we performed immunofluorescence analysis of endog-
enous eIF4E in HeLa cells using a monoclonal antibody, which
recognizes eIF4E in the cytoplasm (Kimball et al., 2003). Al-
though eIF4E is distributed throughout the cytoplasm, it is
Figure 2. 4E-T inhibits cap-dependent translation in
vivo. (A) Schematic presentation of the bicistronic re-
porter plasmid (pGEM-LUC-POLIRES-CAT). HeLa cells
were infected with the vaccinia virus vTF7-3, and trans-
fected transiently with the reporter plasmid and pcDNA3-
4E-T constructs. (B, bottom panel) Western blot analysis
of the transfected cells was performed with anti-4E-T anti-
body. Lane 1, pcDNA3; lane 2, pcDNA3-4E-T; lane 3,
pcDNA3–4E-T–Y30A. The interaction of the wt and mu-
tant 4E-T protein with eIF4E was examined by Far West-
ern analysis (top panel) using a [
32P]-labeled eIF4E
probe. (C) LUC and CAT activity were measured 16 h af-
ter transfection. The LUC/CAT activity ratio is expressed
as a percentage of the control (pcDNA3) set at 100%.
The experiments were performed four times in duplicate. 
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Figure 3.
 
eIF4E colocalizes with 4E-T, Dcp1a, and Dcp2 in P-bodies. 
 
(A) HeLa cells (CCL2) were fixed and the localization of eIF4E was determined by
indirect immunofluorescence with mouse anti-eIF4E monoclonal antibody and Alexa Fluor 594 anti–mouse IgG. The localization of 4E-T was examined
with anti–4E-T and that of Dcp2 with anti-Dcp2 and Alexa Fluor 488 anti–rabbit IgG. The colocalization of these factors appears yellow in the merged image.
(B) The colocalization of endogenous eIF4E with 4E-T and Dcp1a was examined with anti–4E-T and anti-Dcp1a in HeLa S3 as above. The left panel 
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concentrated in foci reminiscent of P-bodies (Fig. 3 A). This
staining pattern is observed in two different HeLa cell sublines:
HeLa CCL2 and HeLa S3 (Carter et al., 1995), but with quali-
tative differences (Fig. 3, A and B–E, respectively), and in
mouse embryo fibroblasts (not depicted). Furthermore, tran-
siently transfected HA-eIF4E also displays a similar cytoplas-
mic distribution pattern (see below, Fig. 4 A).
Double-label immunofluorescence analysis shows that
eIF4E colocalized with 4E-T and Dcp2 in P-bodies (Fig. 3 A).
eIF4E exhibited a more pronounced association with P-bodies
in CCL2 (Fig. 3 A) as compared with HeLa S3 (Fig. 3 B). eIF4E
colocalized with Dcp1a and 4E-T in P-bodies, albeit staining of
eIF4E in these structures is not as apparent as the staining of
4E-T and Dcp1a in HeLa S3 (Fig. 3 B). Strikingly, overexpres-
sion of GFP–4E-T resulted in enhanced staining of eIF4E in
P-bodies (Fig. 3 C). Because localization of eIF4E in P-bodies
was more prominent, and the foci appeared larger and brighter
in GFP–4E-T overexpressing cells than in parental cells, these
data suggest that 4E-T might tether eIF4E to P-body structures.
This effect is illustrated in a graph plotting the intensity of the
eIF4E signal (red channel) in two P-bodies marked by an arrow
in cells overexpressing 4E-T levels (Fig. 3 D, right panel) and
in cells expressing endogenous 4E-T levels (Fig. 3 D, left panel;
the respective P-bodies traversed by the arrow are circled in the
adjacent panel for comparison). The signal intensity of eIF4E
was approximately twofold higher in cells overexpressing 4E-T
as compared with endogenous 4E-T levels, when P-bodies of
weaker intensity were selected from cells overexpressing 4E-T
to avoid signal saturation of the plot. Similar results were ob-
tained with a monoclonal antibody against eIF4E from Trans-
duction Laboratories (610270), and with a monoclonal antibody
(10C6), which recognizes eIF4E predominantly in the nucleus
(Lejbkowicz et al., 1992; Dostie et al., 2000b; unpublished
data). The enhanced eIF4E signal is not due to leakage of the
FITC signal, because no significant signal was detected in
the red channel when cells transfected with GFP–4E-T were
stained with the secondary antibody alone (Fig. 3 E).
To determine whether the association of eIF4E with
P-bodies requires its interaction with 4E-T, we performed im-
munofluorescence analysis using wild-type HA-eIF4E and a
mutant lacking the 4E-T binding site (eIF4E W73A) (Dostie et
al., 2000a). Low eIF4E cDNA amounts were transfected tran-
siently into HeLa cells to obtain a predominantly cytoplasmic
(Dostie et al., 2000a) and P-body localization (Fig. 4 A). Cyto-
plasmic eIF4E levels in HA-eIF4E–expressing cells were similar
to endogenous levels. However, a more pronounced cytoplasmic
foci staining was observed in 
 
 
 
40% of the transfected cells,
presumably because more eIF4E is expressed in these cells. In
contrast, HA-eIF4E W73A did not localize to P-bodies, and
was distributed uniformly between the cytoplasm and the nu-
cleus (Fig. 4 A). Therefore, loss of 4E-T interaction (and also
interaction with eIF4G and 4E-BPs) (Mader et al., 1995) leads
to deregulated cellular localization, which results in diffuse
staining throughout the cell. In addition, because the HA–4E-T
(Y30A) mutant, which is defective in eIF4E binding (Dostie et
al., 2000a), still localizes to P-bodies, these results suggest that
4E-T is required for the association of eIF4E with P-bodies, but
not vice versa (see also Fig. 5 C).
 
demonstrates endogenous eIF4E localization in HeLa S3. Zoomed images (right panel) display colocalization of endogenous eIF4E and Dcp1a in P-bodies.
Some of the more distinct P-bodies are indicated by arrowheads. (C) HeLa cells were transfected with GFP-4E-T and the staining of endogenous eIF4E was
performed with anti-eIF4E antibody as described above. (D) The intensity of fluorescence of endogenous eIF4E in P-bodies from GFP–4E-T–transfected cells
(from panel C) was compared against the intensity of fluorescence of eIF4E from nontransfected cells along the path, which is indicated by the arrow.
The P-bodies along the path of the arrow are circled in the adjacent panel for comparison for better visibility. The signal was allowed to bleach before
quantification to avoid a saturated signal. The graphs plot the intensity of fluorescence against the distance (
 
 
 
m) traversed by the arrow. (E) HeLa cells
transfected with GFP-4E-T were incubated with Alexa Fluor 594 anti–mouse IgG (M-AF594) without previous incubation with anti-eIF4E antibody to
demonstrate the integrity of the green filter.
Figure 4. eIF4E requires interaction with 4E-T for localization to P-bodies,
whereas the other components of the eIF4F complex are excluded from
P-bodies. (A) HeLa cells were transfected with HA-eIF4E wt, HA-eIF4E
W73A, or HA-4E-T Y30A. Localization of proteins was studied by indirect
immunofluorescence with anti-HA (Covance) and Alexa Fluor 594 anti–
mouse IgG. (B and C) HeLa cells were transfected with GFP-Dcp1b and
staining of endogenous eIF4GI (B) or eIF4A (C) was detected with anti-
eIF4GI and Texas Red conjugated anti–rabbit IgG or with anti-eIF4A and
Alexa Fluor 594 anti–mouse IgG. (D) HeLa extract (50 and 100  g) was
resolved by SDS-8% PAGE and a Western blot was performed with rabbit
anti–eIF4GI polyclonal antibody. For eIF4A detection, proteins were re-
solved by SDS-10% PAGE and Western blot was performed with a mouse
anti-eIF4A monoclonal antibody. 
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Because eIF4E is part of the heterotrimeric eIF4F com-
plex, it was important to determine whether eIF4A and eIF4G
also localize to P-bodies. Because 4E-T and eIF4G are expected
to compete for binding to eIF4E, no other eIF4F complex com-
ponents—with the exception of eIF4E—were expected to lo-
calize to P-bodies. To investigate this, the localization of
endogenous eIF4GI and eIF4A was studied in HeLa cells
transfected with GFP-Dcp1b. Western blot analysis with anti-
eIF4A, which recognizes eIF4AI and eIF4AII (Edery et al.,
1983), and anti-eIF4GI revealed protein bands corresponding
to the expected size of the proteins (Fig. 4 D). Immunofluo-
rescence analysis with these antibodies shows that eIF4GI and
eIF4A do not localize to P-bodies because neither protein
colocalizes with the P-body marker, GFP-Dcp1b (Fig. 4, B
and C). Similar results were obtained using two other anti-
eIF4GI antibodies (unpublished data). Thus, eIF4E, but nei-
ther eIF4GI nor eIF4A, localized to P-bodies in vivo. It is
highly likely that eIF4GII behaves in a similar manner, be-
cause it exhibits very similar properties to eIF4GI (Gradi et
al., 1998).
 
Short interfering RNA against 4E-T 
results in decreased localization of 
decapping factors to mammalian P-bodies
 
To investigate whether 4E-T plays a role in the formation of
P-bodies, cellular 4E-T protein levels were reduced by RNA
interference (RNAi). Western blotting (Fig. 5 A) and immuno-
fluorescence analysis (Fig. 5 C) demonstrate that 4E-T was re-
duced strongly (85%) after treatment with a short interfering
RNA (siRNA) against 4E-T, but not by the corresponding in-
verted sequence (4E-T inverted) (Fig. 5 A). Another nonspe-
cific siRNA that was used as a control, 4AIII inverted (Fer-
raiuolo et al., 2004), failed to affect 4E-T protein levels (Fig. 5,
A and C). 4E-T depletion caused Dcp1a and eIF4E to disperse
throughout the cytoplasm and no longer concentrate in foci
(Fig. 5 C; cells that were unaffected in their staining in P-bod-
ies are those that had not taken up the siRNA against 4E-T, as
confirmed by immunostaining with anti-4E-T antibody: not de-
picted). The disappearance of P-bodies was not observed in
cells that were transfected with the nonspecific control siRNA.
No changes in Dhh1p/p54, Dcp1a, and eIF4E protein levels
Figure 5. Depletion of 4E-T from HeLa cells
results in disappearance of decapping factors
from P-bodies. (A) HeLa cells were transfected
with siRNA against 4E-T or control siRNAs
(4AIII inverted or 4E-T inverted). 48 h after
transfection, cells were split into chamber
slides for immunofluorescence analysis [see
(C)] and into a 6-cm dish for Western blot
analysis. 60 h after transfection, protein cell
extracts were prepared and 20  g of extract
was resolved by SDS-10% PAGE. Western
blotting was performed with rabbit anti–4E-T
and anti-eIF4E antibodies, or mouse anti– -
actin monoclonal antibody (Sigma-Aldrich).
4E-T levels were quantified against  -actin,
which served as a loading control, and the
level of protein in the negative control (4AIII
inverted) transfected cells was set as 100. (B)
HeLa extract (20  g) as in (A) was resolved
by 10% SDS-PAGE and Western blotting was
performed with rabbit anti-Dcp1a and anti-
Xenopus p54 (Xp54) antibodies, or monoclo-
nal mouse anti-eIF4E (SK) and anti– -actin an-
tibodies. (C) HeLa (CCL2) cells were trans-
fected with control siRNA (4AIII inverted) or
4E-T siRNA and indirect immunofluorescence
was performed 60 h after transfection with
rabbit anti–4E-T and anti-Dcp1a antibodies,
or monoclonal mouse anti-eIF4E antibody. (D)
HeLa S3 cells were transfected with 4E-T
siRNA or control siRNA (4AIII inverted). 24 h
after transfection, cells were transfected with
myc-EYFP-Me31B; 36 h later, extracts were col-
lected for SDS-PAGE analysis or fixed for im-
munofluorescence. Cell extracts were resolved
by 10% SDS-PAGE and Western blot analysis
with rabbit anti–4E-T, or monoclonal anti-myc
(9E10) and anti– -actin was performed. Indi-
rect immunofluorescence was performed to
assess the localization of 4E-T, and the local-
ization of myc-EYFP-Me31B was assessed by
direct immunofluorescence. The right most pan-
els show the enlarged bordered image. 
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occurred in 4E-T–depleted cells as compared with nonspecific
siRNA controls (Fig. 5, A and B).
The effect of 4E-T depletion on Me31B localization also
was examined (Fig. 5 D). The tagged version of 
 
Drosophila
 
Me31B was used because the antibody against endogenous
p54, used in Fig. 5 B for Western analysis, is not suitable for
immunofluorescence. HeLa cells transfected with 4E-T or
control siRNAs were transfected with the myc-EYFP-Me31B
plasmid, and analyzed by Western blotting and double la-
bel immunofluorescence (Fig. 5 D). 4E-T levels were reduced
efficiently in 4E-T siRNA-treated cells, and the myc-EYFP-
Me31B protein was expressed in cells treated with control or
4E-T siRNAs (left panel). In control cells, myc-EYFP-Me31B
was predominantly cytoplasmic and concentrated in P-bod-
ies (right panel). However, when 4E-T levels were reduced,
Me31B exhibited a diffuse staining pattern throughout the cy-
toplasm and reduced or no staining in P-bodies (right panel).
Thus, reduction of 4E-T protein levels causes mislocalization
of eIF4E and decapping factors away from P-bodies.
 
Cycloheximide inhibits localization of 4E-T 
to P-bodies, whereas leptomycin B 
treatment does not affect its localization
 
In yeast and mammalian cells, cycloheximide treatment re-
leases decapping factors from P-bodies (Sheth and Parker,
2003; Cougot et al., 2004). Cycloheximide inhibits mRNA
translation at the elongation step, which prevents mRNA deg-
radation because of its protection by ribosomes (Ross, 1995).
To study whether 4E-T localization to P-bodies is dependent
on mRNA availability, the effect of cycloheximide on the lo-
calization of 4E-T was examined. HeLa cells were treated with
cycloheximide (10 
 
 
 
g/ml), and analyzed by immunofluores-
cence with anti-Dcp1a and anti–4E-T antibodies. A near com-
plete loss of 4E-T and Dcp1a from P-bodies was observed after
30 min of cycloheximide treatment (Fig. 6 A); this suggested
that the accumulation of 4E-T in P-bodies is dependent on
mRNA availability. This effect is not due to a reduction in
4E-T protein levels. Western blot analysis demonstrates that
the levels of 4E-T and Dcp1a remain unchanged throughout the
cycloheximide treatment (Fig. 6 B). Similar results were ob-
tained in HeLa cells that were transfected transiently with HA-
4E-T (Fig. 6 C, middle panel).
Leptomycin B (LMB) is an inhibitor of chromosome re-
gion maintenance-1–dependent protein nuclear export. We pre-
viously reported that 4E-T is a shuttling protein that exits the
nucleus through the chromosome region maintenance-1 path-
way (Dostie et al., 2000a). Because Dhh1p/p54 also shuttles
between the nucleus and the cytoplasm (Smillie and Sommer-
ville, 2002), it is possible that nuclear export is required for the
localization of 4E-T and decapping factors to P-bodies. To test
this hypothesis, the effect of LMB on the localization of 4E-T
and Dcp1a to P-bodies was studied. LMB treatment resulted in
the accumulation of 4E-T in the nucleus, but did not affect its
association with P-bodies (Fig. 6 C, bottom panel). The distri-
bution of Dcp1a also was unaffected by the drug (bottom
panel). Thus, the presence of 4E-T in P-bodies is dependent on
mRNA, but is independent of its nucleocytoplasmic shuttling.
 
4E-T knockdown increases mRNA half-life
 
The results described above suggest that 4E-T might play a role
in promoting mRNA degradation. To test this hypothesis, we
analyzed the turnover of several mRNAs in 4E-T–depleted and
Figure 6. Effect of cycloheximide and LMB on 4E-T localization in P-bodies. (A) HeLa cells were treated with cycloheximide (CHX; 10  g/ml) for 30 min,
and immunofluorescence staining of 4E-T and Dcp1a were examined as described above. (B) HeLa cell extract (20  g) treated with cycloheximide (CHX;
10  g/ml) for 30 and 60 min was resolved by 10% SDS-PAGE and Western blot analysis with rabbit anti–4E-T and anti-Dcp1a, or monoclonal mouse
 -actin was performed. (C) HeLa cells were transfected with HA–4E-T. 36 h after transfection, the medium was replaced with fresh medium (control) or
medium containing CHX (100  g/ml), and cells were incubated for 3 h before fixation. Alternatively, media containing LMB (5 ng/ml) was added to cells
and incubated for 5 h before fixation. The colocalization of HA–4E-T was determined by indirect immunofluorescence with anti-HA (Covance) and that of
Dcp1a with anti-Dcp1a antibody as described above. The colocalization of HA–4E-T and Dcp1a appears yellow. 
JCB • VOLUME 170 • NUMBER 10 • 2005 920
 
control cells. A 
 
 
 
-globin reporter that is under the control of a
tetracycline-responsive promoter was fused at its 3
 
 
 
 end to one
of two distinct adenine/uridine rich elements (AREs) (Stoecklin
et al., 2004), GM-CSF or 
 
c-fos
 
. The reporter gene—either lack-
ing or containing the ARE—was cotransfected with a plasmid
encoding the activator of transcription (pTet-Off) into HeLa
cells that were transfected previously with 4E-T or control
siRNA. Doxycycline was added to block transcription and RNA
was collected at the indicated times and analyzed by Northern
blotting. As expected, 
 
 
 
-globin lacking an ARE remained stable
throughout the doxycycline treatment, whereas 
 
 
 
-globin con-
taining the GM-CSF or 
 
c-fos
 
 AREs were degraded rapidly, as
was reported previously (Chen et al., 1995) (Fig. 7, A and B).
However, 4E-T diminution in HeLa cells resulted in significant
stabilization (
 
 
 
2-fold) of 
 
 
 
-globin/GM-CSF and 
 
 
 
-globin/
 
c-fos
 
ARE-containing mRNA, with no effect on 
 
 
 
-globin reporter
mRNA lacking an ARE (Fig. 7, A and B). Western blot analysis
demonstrates that 4E-T protein levels were diminished effi-
ciently in HeLa cells that were transfected with the reporter
plasmids and in the presence of doxycycline (Fig. 7 C). The ef-
fect of 4E-T depletion on endogenous 
 
c-fos
 
 mRNA turnover
also was analyzed. Similar to transfected 
 
 
 
-globin containing
the destabilizing element of 
 
c-fos
 
, endogenous 
 
c-fos
 
 was stabi-
lized in the absence of 4E-T (unpublished data).
The stability of the labile p21 mRNA, which contains an
ARE (Lal et al., 2004), also was examined in 4E-T–depleted
cells. Western blotting analysis demonstrates that 4E-T RNAi
strongly reduced the amount of 4E-T (
 
 
 
80%, Fig. 7 D). p21
mRNA stability was determined by Northern blot analysis af-
ter actinomycin D treatment to inhibit de novo transcription.
Figure 7. siRNA-mediated depletion of 4E-T affects mRNA turnover. HeLa cells were transfected with siRNA against 4E-T or a control (Ctrl) siRNA (4AIII
inverted). Protein and RNA were harvested for use in Western (C and D) and Northern (A, B, and E) analysis, respectively. (A and B) HeLa cells were
transfected with siRNA against 4E-T or with control siRNA and later cotransfected with pTet- -globin or pTet- -globin c-fos or GM-CSF ARE and pTet Off.
Cells were treated with doxycycline (1  g/ml)  72 h after transfection to block transcription. Total RNA was isolated at 0.5, 2, 3, and 4 h for  -globin/
GM-CSF ARE assays (A) and 0.5, 1.5, 3, and 6 h for  -globin/c-fos ARE assays (B) and analyzed by Northern blot. GAPDH served as a loading control.
mRNA half-lives were calculated from Northern blots and normalized against GAPDH levels. (C) Protein extracts were collected at 6 h after treatment with
doxycycline (1  g/ml) from cells that were transfected with the reporter plasmid and pTetOff and resolved by SDS-PAGE. Lanes 1 and 4: glo    -globin  
pTetOff; lanes 2 and 5: fos    -globin/c-fos ARE   pTetOff; lanes 3 and 6: GM    -globin/GMCSF ARE   pTetOff. (D) Protein extracts were collected
at the latest time point of actinomycin D treatment and resolved by 10% SDS-PAGE. Western blot analysis was done with anti–4E-T and anti– -actin anti-
bodies. NT   nontransfected. (E) At 48 h after transfection, the half-lives of p21 mRNA were assessed by using actinomycin D (5  g/ml) for the indicated
amount of time. Total RNA (5  g) was resolved on 1.3% formaldehyde gel and analyzed by Northern blotting. 28S levels and 18S levels served as a
loading marker. mRNA half-lives were calculated from Northern blots and normalized against 
32P-labeled 18S levels and plotted on a graph with the
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p21 mRNA levels were quantified in cells that were treated
with 4E-T siRNAs and in nondepleted cells, and normalized to
18S rRNA levels (Fig. 7 E). 4E-T depletion resulted in a mod-
est ( 1.5 fold), but significant, increase in the mRNA half-life
(Fig. 7 E). The difference in p21 mRNA stability achieved with
4E-T depletion is related inversely to that obtained when the
mRNA stabilizer, HuR, is depleted from cells ( 2-fold de-
crease; Lal et al., 2004). Thus, 4E-T promotes degradation of
mRNAs that contain an ARE in their 3  untranslated region.
Discussion
Here we report a new role for 4E-T in mammalian mRNA
degradation. We demonstrate that 4E-T inhibits translation,
colocalizes with decapping factors in cytoplasmic P-bodies,
and decreases mRNA stability. 4E-T interacts with eIF4E
through a shared recognition motif (YXXXXL ) also found in
eIF4G (Dostie et al., 2000a). Similar to other cap-dependent
translation inhibitors, 4E-T is likely to inhibit translation by
competing with eIF4G for binding to eIF4E and preventing for-
mation of the eIF4F complex (Pause et al., 1994; Poulin et al.,
1998). Accordingly, overexpression of 4E-T wt, but not of a
mutant defective in eIF4E binding, strongly inhibited cap-
dependent translation of a reporter mRNA in vivo (Fig. 2).
The transition of an mRNA from a translationally active
mRNP to one destined for decay is believed to be a conse-
quence of translational inhibition, especially in yeast (Tharun
and Parker, 2001; Teixeira et al., 2005). Remarkably, 4E-T is
present in P-bodies, which are cytoplasmic foci containing fac-
tors involved in mRNA decay (Ingelfinger et al., 2002; van
Dijk et al., 2002; Sheth and Parker, 2003; Cougot et al., 2004;
Liu et al., 2004) (Fig. 1). In this study, we also show that eIF4E
is localized to mammalian P-bodies (Fig. 3). Overexpression of
4E-T in HeLa cells caused a marked increase of eIF4E in
P-bodies (Fig. 3). This observation suggests that translation in-
hibition and targeting of eIF4E to P-bodies are causally related.
The accumulation of eIF4E in P-bodies requires interaction
with 4E-T, because an eIF4E mutant that fails to bind to 4E-T
cannot localize to P-bodies (Fig. 4), and depletion of 4E-T re-
sulted in loss of eIF4E from P-bodies (Fig. 5). However, the lo-
calization of 4E-T to P-bodies does not require interaction with
eIF4E, because a 4E-T mutant defective in binding to eIF4E
also localizes to P-bodies (Fig. 4).
eIF4GI and eIF4A did not localize to mammalian pro-
cessing bodies (Fig. 4), which is in agreement with studies that
demonstrated that mRNA pools from P-bodies are distinct
from translating pools (Schwartz and Parker, 1999; Tharun and
Parker, 2001; Teixeira et al., 2005). These observations favor a
model whereby translation inhibition that results from disrup-
tion of the translation initiation complex occurs outside P-bodies,
and precedes P-body formation.
As was shown for Dcp1a (Sheth and Parker, 2003; Cougot
et al., 2004), cycloheximide treatment of HeLa cells reduced
the amount of 4E-T associated with P-bodies (Fig. 6). This re-
sult indicates that ongoing mRNA translation regulates the as-
sociation of 4E-T with P-bodies, and suggests that 4E-T is not a
permanent P-body constituent, but rather localizes to these
structures in an mRNA-dependent manner. Importantly, 4E-T
RNAi treatment results in decreased decapping activity in
HeLa cells as evidenced by diminished localization of Dcp1a
and p54 to P-bodies. Taken together, these data support a
model whereby interaction of 4E-T with eIF4E acts as a prim-
ing event that leads to mRNP remodeling and mRNA decay.
In addition to their role in mRNA decay, P-bodies were
suggested to function as mRNA storage sites (Sheth and
Parker, 2003; Coller and Parker, 2004). For example, the
Drosophila decapping factor Me31B, is concentrated in cyto-
plasmic granules in germline cells where bicoid and oskar
mRNAs are translationally masked (Nakamura et al., 2001). In
addition, the Xenopus equivalent, Xp54, is a major constituent
of maternal mRNA storage particles where translation is re-
pressed (Ladomery et al., 1997; Minshall and Standart, 2004).
Thus, it is possible that under certain conditions, the presence
of eIF4E within P-bodies might permit the transition of a
translationally repressed/stored mRNA to a translationally
competent state.
Homology searches using Blast algorithms failed to iden-
tify 4E-T yeast homologues (Dostie et al., 2000a), and eIF4E
was shown not to localize to P-bodies in yeast (unpublished
data). Therefore, 4E-T might represent a more evolutionarily
complex mRNA decay/storage regulation pathway in higher
eukaryotes. The Drosophila 4E-T homologue, Cup, was re-
ported to mediate translational repression of nanos and oskar
by interacting with eIF4E and 3  trans-acting factors (Wilhelm
and Smibert, 2005). Interestingly, the RNA-binding protein
Smaug, which interacts with Cup, recently was shown to re-
cruit the CCR4 deadenylase complex in Drosophila embryos
(Semotok et al., 2005).
An important finding in this paper is that reduction in 4E-T
results in an increase in mRNA stability (Fig. 7). All of the
mRNAs tested here are ARE-containing mRNAs, which are be-
lieved to be subject to 3 -5  degradation by the exosome, based
on in vitro decay assays (Chen et al., 2001; Mukherjee et al.,
2002). The major deadenylase of AU-containing mRNAs in
mammalian cells is believed to be poly (A) ribonuclease (Gao et
al., 2000; Lai et al., 2003). Therefore, 3 -5 degradation would
require destabilization of the interaction between PABP and
eIF4G to allow entry and association of poly (A) ribonuclease
with the cap (Wilusz et al., 2001). Therefore, 4E-T may insti-
gate the dissociation of PABP from eIF4G by binding to eIF4E
and displacing eIF4G. The decay machinery, which processes
mRNA through the 5 -3  exonucleolytic pathway, is present in
P-bodies. Recent studies have implied that the 5 -3  and 3 -5 
pathways converge at these sites. For instance, mRNA decay
enzymes involved in 5 -3  and 3 -5  decay are recruited by the
ARE binding proteins, tristetraprolin and butyrate response fac-
tor (Lykke-Andersen and Wagner, 2005). Moreover, tristetra-
prolin, which mediates ARE degradation by recruiting the exo-
some (Chen et al., 2001), also is found localized in P-bodies
(Kedersha et al., 2005). Because the disappearance of P-bodies
with 4E-T RNAi was not synonymous with complete stabiliza-
tion of p21 mRNA, it is possible that this process occurs outside
of P-bodies or that its deadenylation/decay occurs by way of a
distinct pathway from c-fos and GM-CSF mRNAs.JCB • VOLUME 170 • NUMBER 10 • 2005 922
In conclusion, the interaction of 4E-T with eIF4E in cells
has two consequences: import of eIF4E to the nucleus (Dostie
et al., 2000a) and the targeting of eIF4E to sites of mRNA de-
cay. The function of eIF4E in the nucleus is under investiga-
tion; a proposed nuclear function of eIF4E is to export a subset
of mRNAs from the nucleus (Lai and Borden, 2000; Rousseau
et al., 1996). The dual role of 4E-T also might serve to seques-
ter the limiting factor in translation initiation, eIF4E, as a
means of maintaining translational homeostasis. It will be im-
portant to examine how 4E-T is regulated. It is reported that
4E-T is a phosphoprotein (Pyronnet et al., 2001); therefore, it
would be interesting to know what pathways regulate its phos-
phorylation and activity.
While this paper was under review, two reports were pub-
lished which demonstrated that eIF4E is found in P-bodies
(Andrei et al., 2005; Kedersha et al., 2005), and that 4E-T is
also concentrated in P-bodies (Andrei et al., 2005).
Materials and methods
Plasmids and cell culture
HA–4E-T, HA–4E-T (Y30A), HA-eIF4E, HA-eIF4E (W73A) (Dostie et al.,
2000a), and GFP-Dcp1b (Cougot et al., 2004) were described previ-
ously. GFP–4E-T was generated by subcloning the coding region of 4E-T
from pcDNA3-4E-T (Dostie et al., 2000a) into pFRED143 (provided
by G. Pavlakis, National Cancer Institute, Frederick, MD). Myc-EYFP-Me31B
plasmid was a gift from A. Nakamura (University of Tsukuba, Tsukuba,
Japan).
Construction of tetracycline-regulated  -globin expression plas-
mids. The starting plasmid, CMV-glo-SPA, which contains the human  -globin
gene with the 3  untranslated region and polyadenylation site replaced
with a multiple cloning site and a strong synthetic polyadenylation ele-
ment (SPA), was described previously (Das Gupta et al., 1998). The first
generation tetracycline-regulated globin construct pTet-O- Ac-glo-SPA
was prepared by digesting CMV-glo-SPA with HindIII, end-filling with
Klenow fragment DNA polymerase, then digesting with NcoI. The globin-
SPA fragment was gel purified and cloned into pGTetO AcLuc3 (pro-
vided by J. Garcia-Sanz, Universidad Autãnoma, Madrid, Spain) in
which the LUC insert was removed by digesting with BamHI, followed
by end-filling with Klenow fragment DNA polymerase plus digestion
with NcoI. The c-fos ARE was recovered from the plasmid pBBB ARE
cfos
(provided by A.-B. Shyu, University of Texas Medical School, Houston,
TX) by PCR amplification with primers BBBARE1 (5 -CGCTCTAGACAG-
AAGGTGGTGGCTGGTGTG-3 ) and BBBARE2 (5 -GCGTCTAGACT-
CAAGGGGCTTCATGATGTC-3 ). The GM-CSF ARE was recovered simi-
larly by PCR from pBBB ARE
GM-CSF using primers BBBARE1 and BBBARE3
(5 -CCCTCTAGAGCTGGTTATTGTGCTGTCTCA-3 ). The PCR products
were digested with XbaI and inserted into XbaI-digested Tet-O- Ac-glo-
SPA to create plasmids pTet-O- Ac-glo-ARE[cfos]-SPA and pTet-O-
 Ac-glo-ARE[GM-CSF]-SPA. These were used to prepare the second-gen-
eration plasmids that were used in this study. The region spanning the
tetracycline operator and  -actin promoter elements of each of these
plasmids was removed by digestion with Nhe1 and Nco1, and re-
placed with the region spanning the tetracycline operator elements and
minimal CMV promoter regions of pTREmyc. The latter was prepared
by PCR amplification of pTREmyc using primers BM127 (5 -ATGCCAT-
GGTGTCTAGCACGCG-3 ) and BM128 (5 -CCGCTAGCCACGAG-
GCCCTTTCGTCTCG-3 ). The final plasmids are designated pTet-CM-
Vmin-glo-SPA, pTet-CMVmin-glo-ARE[cfos]-SPA, and pTet-CMVmin-glo-ARE
[GM-CSF]-SPA.
HeLa S3 cells from M. Wilkinson (M.D. Anderson Cancer Center,
Houston, TX) (Carter et al., 1995) and HeLa CCL2 (American Type Culture
Collection) were cultured in DMEM supplemented with 10% FBS. HeLa S3
cells usually were used unless specified otherwise.
siRNA transfections
siRNA annealed duplexes were purchased from Dharmacon and se-
quences are listed below. HeLa cells were transfected at 30% confluency
in 6-well plates with siRNA (300 pmole final) using oligofectamine accord-
ing to the manufacturer’s instructions. siRNA complexes were left over-
night, and cells were processed 48 to 72 h later. 4E-T siRNA 5 -GAA-
CAAGAUUAUCGACCUA dTdT-3 ;  4AIII inverted 5 -CGACCAGAG-
CTTAAGGTGA dTdT-3 ; 4E-T inverted 5 -CGUACCGUGGAAUAGUUCC
dTdT-3 .
Transient transfections and immunofluorescence
Transfections of DNA plasmids were performed by the calcium phosphate
method as described previously (Dostie et al., 2000a). HeLa cells were
transfected at 50% confluency with 5  g (or 8  g for GFP-4E-T) of plasmid
DNA, and were processed 36 h after transfection. For transfection of myc-
EYFP-Me31B (Fig. 5 D), siRNA transfections were performed in 6-well
plates as described above; after 24 h, 2  g of myc-EYFP-Me31B was
transfected by the calcium phosphate method. 48 h after siRNA transfec-
tion, cells were trypsinized into chamber slides and processed for immuno-
fluorescence 12 h later. Immunofluorescence was performed as described
previously (Dostie et al., 2000a). In brief, cells were plated onto Lab-Tek
chamber slides (Nunc) 16 h before fixation. Cells were fixed with formalde-
hyde, permeabilized, blocked, and incubated with affinity-purified rabbit
anti–4E-T (1:100) (Dostie et al., 2000a), affinity-purified rabbit anti-Dcp1a
(1:200) (a gift from J. Lykke-Andersen, University of Colorado, Boulder, CO),
and anti-Dcp2 (1:20) (Liu et al., 2004) antibodies, or monoclonal anti-
eIF4A (1:100) (Edery et al., 1983), anti-eIF4E (1:10) (Kimball et al.,
2003), and anti-HA (1:1,000) (Covance) antibodies for 2 h at RT. Cells
were washed extensively and incubated with Texas red or AlexaFluor
488 or 594 conjugated secondary antibody (1:200) (Molecular Probes)
for 30 min. Nuclei were stained with Hoechst dye 33258 (Sigma-
Aldrich). Images were taken from a 63  objective of a Zeiss LSM 510
confocal microscope. Immunofluorescence analysis for each experiment
was performed three to five times, and the most representative results
are displayed.
Western blotting
Cells were washed twice with ice cold PBS and pelleted at maximum
speed for 10 min in a microcentrifuge. Cell pellets were frozen on dry ice
and thawed in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1%
Nonidet P-40, 0.5% SDS, and a mixture of protease inhibitors [Roche Di-
agnostics]). Extracts were incubated on ice for 10 min and centrifuged for
5 min at maximum speed to recover the supernatant. Proteins were re-
solved by SDS/PAGE, transferred to nitrocellulose membrane, blocked,
and incubated with rabbit anti–4E-T (1:1,000) (Dostie et al., 2000a), anti-
Dcp1a (1:1,000), anti-Xp54 (1:2,000) (Smillie and Sommerville, 2002),
and anti-eIF4E 5851 (1:1,000) (Frederickson et al., 1991) polyclonal an-
tibodies or monoclonal anti-eIF4A (1:1,000) (Edery et al., 1983), anti-
eIF4E (1:100) (Kimball et al., 2003), anti-HA (1:2,000) (Covance), and
anti- -actin (1:5,000) (Sigma-Aldrich) antibodies.
Vaccinia virus infection, Far Western analysis, and translation assay
HeLa cells (80% confluency) were infected with recombinant vaccinia virus
for 1 h at 37 C (Fuerst et al., 1986). Cells were rinsed once with serum-
free media and transfected with 5  g each of the reporter plasmid
(pGEM-LUC-POLIRES-CAT) and pcDNA3–4E-T wt or mutant constructs us-
ing lipofectin (15  g; Invitrogen) as previously reported (Pause et al.,
1994). After 16 h, cell extracts were collected and analyzed for LUC ac-
tivity using a LUC assay system (Promega), and activity was measured
with a luminometer; CAT expression was analyzed using ELISA (Boeh-
ringer). Far Western analysis was performed on transfected cell extracts
as described previously (Dostie et al., 2000a)
Northern blotting
Total RNA was isolated using a QIAGEN RNAeasy kit according to the
manufacturer’s instructions. 5  g of total RNA was separated on a 1.3%
agarose/formaldehyde gel, transferred to a Hybond-N membrane (GE
Healthcare), and probed with 
32P-labeled, random-primed DNA probe to
detect p21 (Lal et al., 2004) or 
32P-end labeled oligonucleotide, using ter-
minal deoxynucleotidyl transferase (Invitrogen), to detect 18S rRNA (Lal et
al., 2004). For  -globin reporter assays, 4E-T or control siRNA was trans-
fected into HeLa cells as described above. 36 h later, pTet- -globin re-
porter plasmids and pTet Off (encoding for tTA, transactivator) were
cotransfected. 12 h later, cells were split 1:6 and treated 16 to 20 h later
with doxycycline (1  g/ml). RNA was resolved on a formaldehyde gel as
above and probed with 
32P-labeled, random-primed DNA probe for de-
tecting  -globin (Stoecklin et al., 2004) or GAPDH.
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